First-in-human Mutation-targeted siRNA Phase Ib Trial of an Inherited Skin Disorder
Open Access
- 1 February 2010
- journal article
- research article
- Published by Elsevier BV in Molecular Therapy
- Vol. 18 (2), 442-446
- https://doi.org/10.1038/mt.2009.273
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- siRNA silencing of keratinocyte-specific GFP expression in a transgenic mouse skin modelGene Therapy, 2009
- Knocking down barriers: advances in siRNA deliveryNature Reviews Drug Discovery, 2009
- The promises and pitfalls of RNA-interference-based therapeuticsNature, 2009
- Stability Study of Unmodified siRNA and Relevance to Clinical UseOligonucleotides, 2008
- Therapeutic siRNAs for dominant genetic skin disorders including pachyonychia congenitaJournal of Dermatological Science, 2008
- The Business of RNAi TherapeuticsHuman Gene Therapy, 2008
- Sequence- and target-independent angiogenesis suppression by siRNA via TLR3Nature, 2008
- Clinical and Pathological Features of Pachyonychia CongenitaJournal of Investigative Dermatology Symposium Proceedings, 2005
- Overcoming Functional Redundancy To Elicit Pachyonychia Congenita-Like Nail Lesions in Transgenic MiceMolecular and Cellular Biology, 2005
- An Inducible Mouse Model for Epidermolysis Bullosa SimplexThe Journal of cell biology, 2001